Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who were 18 years of age or older at the time their tissue sample was taken or consent was given
- People for whom a consent form or non-opposition form is available allowing their samples to be used for research aligned with the study's goals (or where local ethics approval permits sample use without this)
- People who have a confirmed diagnosis of the relevant cancer type, based on internationally recognised diagnostic standards
- People for whom a preserved tissue sample (stored in a specific way known as formalin-fixed, paraffin-embedded, or FFPE) is available and suitable for generating the required research data
- People for whom associated medical/clinical records are available to accompany their tissue sample
- People whose tissue block meets all of the following conditions: it contains the expected cancer type; for most solid cancers, the tumour cells make up between 40% and 80% of the sample in the area tested; for a specific blood cancer called diffuse large B cell lymphoma (DLBCL), at least 80% of the sample must be high-grade tumour; wherever possible, the remaining tissue thickness must be greater than 125 micrometres; and the tumour sample must be less than 10 years old
- Each specific cancer group within the study may have additional inclusion requirements (such as disease stage, where the sample was taken from, or treatments previously received) — confirm with trial site for details relevant to a specific cancer type
Who may not be able to join:
- People whose only available samples are in a liquid or loosely processed form (such as cytology samples or cytoblocks), which do not preserve the tissue's structure
- Each specific cancer group within the study may have additional reasons a person may not be eligible (such as a particular cancer subtype or a history of immune system suppression) — confirm with trial site for details relevant to a specific cancer type
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Dr. Vassili Soumelis, Owkin
Phone: +33 6 45 63 71 12
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary endpoint will be genes or proteins that present features compatible with drug targeting and/or novel biomarkers, and that are specific to a given patient population within one or more cancer indications.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.